What are the recommended dosing regimens for Tolvaptan in autosomal dominant polycystic kidney disease and for eu‑ or hypervolemic hyponatremia?

Tolvaptan Dosing

For Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Initiate tolvaptan at 45 mg in the morning and 15 mg eight hours later, then uptitrate weekly to a target dose of 90 mg morning/30 mg afternoon based on tolerability. 1

Initiation and Titration Protocol

• Starting dose: 45 mg upon waking, followed by 15 mg eight hours later 1
• First uptitration (≥1 week): 60 mg morning/30 mg afternoon 1
• Target dose (≥1 week later): 90 mg morning/30 mg afternoon 1
• Continue treatment until approaching kidney replacement therapy 1

Key Dosing Considerations

• The split-dose regimen is necessary to suppress urine osmolality to <300 mOsm/kg for 24 hours 2
• The 45/15 mg starting regimen suppresses urine osmolality in >50% of patients and is well tolerated 2
• The 90/30 mg target dose suppresses urine osmolality in 85% of patients, though only 61% (28/46) tolerate uptitration to this level due to aquaretic side effects 2
• Real-world data shows most patients maintain lower dosages (≤45/15 mg) than used in clinical trials, with two-thirds undergoing net dosage decreases 3

When to Hold or Reduce Dosing

Patients must skip tolvaptan doses during "sick days" when at risk of volume depletion: 1

• Limited access to water
• Increased fluid losses (vomiting, diarrhea, fever)
• Activities in warm weather
• Any situation preventing adequate fluid intake

Consider downtitration or holding tolvaptan with: 1

• Concurrent strong CYP3A inhibitors (itraconazole, ketoconazole, clarithromycin, ritonavir) 1, 4
• Concurrent moderate CYP3A inhibitors (fluconazole, erythromycin, diltiazem, verapamil, grapefruit juice) 1
• Intolerance or aquaretic side effects 1
• Liver enzyme elevations 1

Drug Interactions Requiring Dose Adjustment

• Strong CYP3A inhibitors are contraindicated - they reduce tolvaptan clearance by >80% 1, 4, 5
• Moderate CYP3A inhibitors should be avoided - they reduce clearance by 50-80% 1
• Strong CYP3A inducers should be avoided as they may reduce tolvaptan efficacy 5

---

For Eu- or Hypervolemic Hyponatremia

Initiate tolvaptan at 15 mg once daily in a hospital setting, then increase at ≥24-hour intervals to 30 mg daily, and if needed to a maximum of 60 mg daily, based on serum sodium response. 5

Initiation Requirements

• Must initiate and re-initiate in a hospital where serum sodium can be monitored closely 5
• This is a boxed warning due to risk of osmotic demyelination syndrome from overly rapid sodium correction 5
• Avoid fluid restriction during the first 24 hours to prevent overly rapid correction 5

Titration Schedule

• Starting dose: 15 mg once daily 5
• First increase (≥24 hours): 30 mg once daily 5
• Maximum dose (≥24 hours): 60 mg once daily 5
• Titrate to achieve serum sodium >135 mEq/L or maximum dose of 60 mg 5

Duration of Treatment

• Limit treatment duration to maximum 30 days 4, 5
• This limitation is due to hepatotoxicity risk 5
• Serum sodium typically increases within 8 hours and is maintained for 30 days 5
• Upon discontinuation, sodium levels decline to baseline within 7 days 5

Monitoring During Hyponatremia Treatment

• Check serum sodium at 8 hours after first dose 5
• Monitor daily for first 72 hours during titration 5
• Conduct frequent serum sodium measurements and neurologic assessments during initiation and dose changes 4
• Monitor for osmotic demyelination syndrome manifestations: dysphagia, seizures, dysarthria, lethargy, affective changes 4, 5
• Avoid correction >12 mEq/L per 24 hours 5

Contraindications for Hyponatremia Indication

• Patients unable to respond appropriately to thirst 5
• Hypovolemic hyponatremia 5
• Anuria 5
• Patients requiring urgent correction to prevent serious neurological symptoms 5

---

Universal Monitoring Requirements

Hepatotoxicity Monitoring (Critical for Both Indications)

For ADPKD patients on long-term therapy: 4

• Monthly liver function tests (LFTs) for first 18 months 4
• Every 3 months thereafter until discontinuation 4
• Obtain morning blood sample before tolvaptan dose 4

Action thresholds: 1

• Hold tolvaptan if AST/ALT ≥3× upper limit of normal (ULN) or >2× baseline 1
• Hold if AST/ALT >2× ULN with symptoms (fatigue, nausea, vomiting, right upper quadrant pain, jaundice, pruritus) 1
• Repeat LFTs within 48-72 hours 1
• Permanently discontinue if levels remain ≥3× ULN unless alternative explanation identified 1
• Approximately 5% of ADPKD patients develop transaminase elevations >3× ULN (vs 1% on placebo) 4
• Drug-induced liver injury typically occurs within first 18 months 4

Fluid and Electrolyte Monitoring

• Monitor serum sodium regularly to ensure adequate water intake 4
• Patients must drink 2-3 liters of water daily, spread throughout the day 1
• Counsel patients to drink liquids without sugar or fat and adopt low-sodium intake to reduce polyuria 1
• Monitor for hypernatremia (generally mild) and hyponatremia (can occur with excessive water intake) 6
• Monitor serum potassium in patients with K+ >5 mEq/L or on potassium-raising medications 5

Common Aquaretic Side Effects

• Thirst: 16% of patients 4
• Dry mouth: 8.4% of patients 4
• Polyuria and increased urinary frequency: common 4
• These effects are consistent with the drug's mechanism of action and often limit tolerability 1, 3

Additional Monitoring

• Monitor for hyperuricemia and rarely gout 1
• Assess weight and volume status to detect dehydration 7
• Female patients may experience higher discontinuation rates due to side effects 3